ATMA CENA
All articles

The Preparation Phase of Psychedelic-Assisted Therapy in Canada (2026)

16 min read
A calm, softly lit therapy room with two comfortable chairs, a woven blanket, and a small side table, set up for a psychedelic-assisted therapy preparation session.

In Canada, psychedelic-assisted therapy is delivered in three phases: preparation, dosing, and integration. The preparation phase is the structured clinical work done before the first session, screening, alliance-building, medication review, intention-setting, and informed consent. It is not optional; it is the foundation on which safe and effective dosing depends.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

  • Preparation accomplishes ten distinct clinical functions before any dosing occurs: intake, history review, medication review, therapeutic alliance, expectation-setting, psychoeducation, practical planning, grounding skills, intention-setting, and contraindication screening.
  • Preparation length varies by substance: 1–3 sessions for ketamine / KAP; 2–4 sessions for psilocybin therapy; 3 structured sessions for MDMA-assisted therapy per the MAPP Phase 3 protocol [Mitchell 2021; Mitchell 2023].
  • Medication review is clinically critical: SSRIs and SNRIs are generally tapered before psilocybin and MDMA dosing under medical supervision; MAOIs are an absolute contraindication for MDMA; ketamine does not require antidepressant tapering.
  • Patients must never stop, taper, or change psychiatric medications without the direct supervision of their prescribing physician.
  • Poor preparation is associated with more difficult dosing experiences and weaker integration across the RCT and clinical-observation literature [Hartogsohn 2017; Carbonaro 2016].
  • No amount of preparation guarantees a specific outcome. Response in psychedelic-assisted therapy remains individualized.

If you are evaluating whether psychedelic-assisted therapy is right for your situation, book a free 15-minute information call with ATMA CENA's clinical team before you commit to anything.

What the preparation phase is

The preparation phase is the first of three phases in the standard psychedelic-assisted therapy model: preparation, dosing, and integration. It encompasses every clinical encounter that happens before the patient enters a dosing session. In Canada, this model is the standard frame across reputable programs delivering ketamine-assisted psychotherapy (KAP), psilocybin therapy, and MDMA-assisted therapy (MDMA-AT). Psilocybin and MDMA therapy are accessible in Canada only when Health Canada grants approval on a case-by-case basis, initiated by a physician. The model originates in the MAPS MDMA-AT protocols [Mithoefer 2011], the Imperial College London psilocybin trials [Carhart-Harris 2016], and the COMPASS COMP360 psilocybin study [Goodwin 2022]. Preparation is where the clinical team screens for contraindications, establishes trust with the patient, reviews and plans around medications, sets expectations, and builds the psychoeducation and psychological skills the patient will need in the dosing room. It is the part of the model most commonly under-resourced by lower-quality providers and most consistently correlated with better outcomes in the clinical literature.

What preparation accomplishes: ten clinical functions

Preparation is not waiting-room time before the medicine. It is structured clinical work with ten distinct purposes.

1. Comprehensive intake and medical screening

The preparation phase begins with a comprehensive intake: medical history (cardiovascular, endocrine, neurological, hepatic), surgical history, current medications and supplements, allergies, substance use history, and a structured psychiatric history. For ketamine and esketamine, blood pressure baseline and cardiovascular screening are routine. For psychedelics, screening for personal and family history of psychotic disorders is non-negotiable.

2. Clinical history review and treatment goals

The clinician reviews prior treatments, pharmacotherapy trials, psychotherapy modalities, dose adequacy, duration, response, and tolerability, and discusses what the patient is hoping to address. This anchors preparation in concrete, individualized goals rather than generic outcome talk.

3. Medication review and taper planning

Medication review is one of the most clinically important components of preparation. How this plays out differs substantially by substance.

For psilocybin: SSRIs and SNRIs blunt the acute subjective intensity of psilocybin in a substantial proportion of users; approximately 50% of participants in self-report studies described attenuated effects. Multiple psilocybin clinical trials, including the COMP360 Phase 2b trial [Goodwin 2022] and the psilocybin-versus-escitalopram trial [Carhart-Harris 2021], tapered antidepressants over 2–4 weeks with a minimum two-week washout before dosing. A 2024 secondary analysis found a partial dissociation between acute psychedelic intensity and antidepressant outcome [Erritzoe 2024]; a prospective RCT comparing taper versus continue has not yet been conducted as of 2026.

For MDMA: SSRIs and SNRIs attenuate MDMA's subjective and therapeutic effects via shared serotonin-reuptake transporter mechanisms. The MAPP1 and MAPP2 Phase 3 protocols required supervised tapering and washout of psychiatric medications before the first experimental session [Mitchell 2021; Mitchell 2023]. MAOIs are an absolute contraindication for MDMA due to the risk of life-threatening serotonin syndrome and hypertensive crisis; the MAPP protocols required a minimum 14-day MAOI washout before any MDMA exposure.

For ketamine: SSRIs and SNRIs do not attenuate ketamine's antidepressant effect and are generally continued during ketamine treatment [Veraart 2021]. Benzodiazepines above approximately 8 mg diazepam-equivalent daily have been shown to significantly reduce ketamine's antidepressant effect and are sometimes held the day of dosing [Andrashko 2020].

In all cases, the prescribing physician makes the taper decision. Patients must never stop, taper, or change psychiatric medications without the direct supervision of their prescribing physician.

Watch out: Self-tapering antidepressants without medical supervision carries real clinical risk. Abrupt discontinuation of SSRIs and SNRIs causes discontinuation syndrome; abrupt benzodiazepine cessation can cause seizures. Any medication change before psychedelic-assisted therapy must be physician-supervised.

4. Establishing therapeutic alliance

The patient meets the team present in the dosing session. In MAPP-style PAT protocols this is a male-female co-therapy pair; in psychedelic protocols it is typically a lead therapist and co-therapist or sitter; in PAT it varies by clinic. The point of preparation is that the patient enters dosing having already established trust with the people in the room. Therapeutic alliance is one of the most consistent predictors of psychotherapy outcome across modalities [FlΓΌckiger 2018].

5. Set and setting

Preparation intentionally constructs both set (the patient's mindset, expectations, intentions, and current state) and setting (the physical and relational environment of dosing). The set-and-setting framework, originally described by Leary, Litwin, and Metzner [1963] and re-formalized by Hartogsohn [2017], is among the better-evidenced predictors of psychedelic experience quality. Leaving either to chance increases the likelihood of difficult experiences. For a full discussion, see Set and Setting in Psychedelic-Assisted Therapy.

6. Trauma-informed psychoeducation

Patients are educated on what the substance does pharmacologically, what subjective effects to expect, and what kinds of phenomena, vivid imagery, emotion surfacing, body sensations, ego dissolution at higher psilocybin doses, are normal versus signals to communicate to the team. Trauma-informed framing reduces the likelihood that intense material in the dosing session is destabilizing rather than therapeutic.

7. Practical planning

Preparation covers logistics: identifying a support person for transport and same-day care; confirming the patient cannot drive after dosing; booking a post-session day off work; scheduling the first integration appointment within 24–72 hours of dosing. Skipping practical planning is a common reason a clinically successful dosing session translates poorly into integration.

8. Anchor and grounding skills

Patients practise grounding skills, paced breathing, body scans, orienting techniques, simple somatic interventions, before dosing. These are the same skills available during the session if a difficult moment arises. Practising before the medicine is administered means the patient has the skill in their nervous system, not merely their head.

9. Intention-setting

Intention-setting is the patient articulating what they hope to explore, change, or sit with during dosing. Intentions are specific to the patient's goals and are not outcome promises. They become reference points during dosing and integration alike.

Pro tip: Intentions work best when they are specific and open rather than outcome-focused. "I want to look at the role of my father in my drinking" is more useful than "I want to stop drinking." The difference is one between inquiry and demand.

10. Safety and contraindication screening

Standard contraindication screens include: personal history of psychotic disorder; first-degree-relative family history of psychotic disorder (especially for psilocybin and MDMA); uncontrolled cardiovascular disease; pregnancy and lactation; Bipolar I disorder (relative or absolute contraindication depending on substance and protocol); and active suicidal ideation with plan and means. A patient who does not meet safety criteria cannot be prepared into eligibility. These screens are the most important reason the preparation phase exists.

Wondering if this is right for you?

Talk it through with our clinical team on a free call. No referral needed to start.

How preparation differs by substance

Although the ten functions above apply across substances, preparation structure differs meaningfully by substance.

Substance Typical preparation sessions Typical timeline Psychotherapy emphasis
Ketamine (off-label KAP) 1–3 sessions 1–3 weeks Moderate; increasing in evidence base
Spravato (esketamine) Onboarding + 1–2 sessions 1–2 weeks Lower; label requires in-clinic monitoring
Psilocybin 2–4 sessions 2–4 weeks Substantial; COMP360-style protocol
MDMA-AT (MAPP-style) 3 structured 90-minute sessions 3–6 weeks Heavy; MAPP1/MAPP2 protocol

Ketamine and esketamine: KAP preparation has historically been 1–3 sessions, with less psychotherapy emphasis than psilocybin or MDMA protocols. That said, the KAP literature increasingly documents outcome differences between psychotherapy-supported ketamine and infusion-only ketamine [Dore 2019; Mathai 2023]. For esketamine (Spravato), in-clinic monitoring is mandatory per the Health Canada label; preparation overlaps substantially with onboarding.

Psilocybin: Preparation in current Canadian protocols is typically 2–4 sessions over 2–4 weeks with substantial psychotherapy emphasis, following COMP360-style structure [Goodwin 2022].

MDMA-AT: Preparation per the MAPP1 [Mitchell 2021] and MAPP2 [Mitchell 2023] protocols is 3 structured 90-minute preparation sessions with heavy emphasis on therapeutic alliance, trauma psychoeducation, and the inner-directed approach. MDMA-AT remains accessible in Canada only when Health Canada grants approval on a case-by-case basis, initiated by a physician; preparation generally follows MAPP-style protocols.

ATMA CENA calibrates preparation length, duration, and sequencing to each person's substance pathway, clinical history, and goals rather than to any fixed trial protocol.

Not sure where to start?

A free 15-minute call clarifies your options and the next steps for your situation.

Why preparation matters: what the evidence shows

Three patterns recur across the controlled-trial and clinical-observation literature:

  1. Poor preparation predicts difficult dosing experiences. Quality of set-and-setting, including the patient's preparation and trust in the team, is among the better-evidenced predictors of subjective experience quality and acute-distress likelihood [Hartogsohn 2017; Carbonaro 2016]. In a survey of 1,993 individuals describing their most psychologically difficult psilocybin experience, 84% nonetheless endorsed long-term benefit from the experience, but this was in uncontrolled naturalistic use [Carbonaro 2016]. Supervised, screened, and prepared participants have substantially better safety profiles.
  2. Poor preparation predicts weaker integration. Patients who enter dosing without articulated intentions, without practical post-session plans, and without alliance with the team report greater difficulty making sense of the experience and translating it into change.
  3. Adverse events cluster in inadequately screened or inadequately prepared patients. Adverse-event reporting in psilocybin and MDMA RCTs concentrates in patients whose contraindication screening was suboptimal.

The COMP360 protocol [Goodwin 2022], the MAPP1/MAPP2 protocols [Mitchell 2021; Mitchell 2023], and the original Mithoefer MDMA-AT protocols [Mithoefer 2011] all build in 2–6 weeks of structured preparation for reasons supported by trial-level evidence rather than tradition.

Have questions about your situation?

Our team can walk you through eligibility, preparation, and what to expect.

What preparation does not do

  • Preparation does not guarantee a good dosing experience. Even well-prepared patients can have challenging sessions. The team's job is to support the patient through difficult material, not to prevent all difficulty.
  • Preparation does not guarantee a good outcome. Response is individualized. The 25 mg psilocybin arm of the COMP360 trial showed 37% response and 29% remission at week 3 [Goodwin 2022]; meaningful, but not universal.
  • Preparation cannot substitute for screening. A patient who does not meet safety criteria cannot be prepared into eligibility.
  • Preparation cannot replace integration. Strong preparation makes integration possible; it does not perform integration in advance.

If you would like to talk through what the preparation phase would look like for your specific situation, book a free information call with ATMA CENA's clinical team.

Frequently asked questions

How many preparation sessions will I have?

It depends on the substance, the clinic, and your clinical history. Typical ranges: 1–3 sessions for ketamine / KAP; 2–4 for psilocybin therapy; 3 structured sessions for MDMA-AT per the MAPP-style protocol. ATMA CENA calibrates preparation length to your specific substance, history, and goals.

Can preparation sessions be done virtually?

Some components, intake interviews, history review, psychoeducation, intention-setting, can be conducted virtually. Other components, particularly grounding-skills practice with the dosing team and final clinical clearance, are typically in person. ATMA CENA's CoCare model accommodates blended in-person and virtual preparation for patients with existing therapeutic relationships.

Do I need to taper my antidepressants before psychedelic-assisted therapy?

This is a clinical decision made by your prescribing physician, not a decision you should make on your own. For psilocybin and MDMA, most clinical trials required a supervised taper and washout of SSRIs and SNRIs before dosing. For psychedelics, most psychiatric medications continue concurrently. MAOIs are an absolute contraindication for MDMA. Patients must never stop, taper, or change psychiatric medications without the direct supervision of their prescribing physician.

What if I have a family history of psychotic disorders?

Family history of psychotic disorders is one of the most important screening criteria for psychedelics. Personal history of psychosis is generally an absolute contraindication; first-degree-relative family history is a strong relative contraindication, assessed case by case. Ketamine has a different evidence profile and is sometimes accessible in patients for whom psilocybin or MDMA is not.

Can my existing therapist be part of preparation?

Through ATMA CENA's CoCare program, we can partner with your therapist if they have the appropriate training and build a service agreement with us. Where clinically appropriate, preparation explicitly includes coordination with them. See ATMA CENA CoCare.

What is "set and setting" and why is it part of preparation?

"Set" is the patient's mindset, expectations, intentions, and current state going into dosing. "Setting" is the physical and relational environment of the dosing session. The set-and-setting framework, originally described by Leary, Litwin, and Metzner [1963] and re-formalized by Hartogsohn [2017], is among the better-evidenced predictors of psychedelic experience quality. Preparation is where both are intentionally constructed rather than left to chance. See Set and Setting in Psychedelic-Assisted Therapy.

What if I do not feel ready by the end of preparation?

Then the dosing session is rescheduled. Preparation that ends with the patient not feeling ready is preparation working as designed. Any provider who pressures a patient to dose before they feel ready is a clinical red flag.

Is preparation covered by insurance?

Coverage is substance- and programme-specific. Spravato onboarding and preparation are often covered alongside the medication. KAP psychotherapy hours sometimes attract psychotherapy-benefit coverage. Psilocybin and MDMA therapy are not generally covered by Canadian private insurance.

Informed consent is a structured conversation covering substance pharmacology, expected and possible effects, risks, contraindications, alternatives including doing nothing, the limits of current evidence, costs, and the patient's right to withdraw at any point. It is part of preparation by design. Informed consent at the door of the dosing room is too late.

Why is preparation described as "non-optional"?

Every component of preparation has a specific clinical purpose: screening prevents harm; education reduces unhelpful surprise; intention-setting shapes the dosing experience; alliance-building supports difficult moments in the room; practical planning protects the post-session window; informed consent protects patient autonomy. A programme that frames preparation as optional has not internalized the evidence base it claims to operate from.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act (Schedule III and Schedule I respectively). Patient access to psilocybin- or MDMA-assisted therapy is available only when Health Canada grants approval on a case-by-case basis, initiated by a physician, and approval is not guaranteed. Case-by-case psilocybin access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness; case-by-case MDMA access is primarily granted for adults with PTSD. Ketamine is approved by Health Canada as an anaesthetic; use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (e.g., CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba). Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression in adults aged 18–64. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

  1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025–1033. PMID: 33972795. https://www.nature.com/articles/s41591-021-01336-3
  2. Mitchell JM, Ot'alora GM, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473–2480. PMID: 37709999. https://www.nature.com/articles/s41591-023-02565-4
  3. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP360). New England Journal of Medicine, 387(18):1637–1648. PMID: 36322843. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
  4. Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7):619–627. PMID: 27210031.
  5. Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402–1411. PMID: 33852780.
  6. Mithoefer MC, Wagner MT, Mithoefer AT, et al. (2011). The safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4):439–452. PMID: 20643699.
  7. Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12):1268–1278. PMID: 27578767.
  8. Hartogsohn I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3:1–17.
  9. Leary T, Litwin GH, Metzner R. (1963). Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease, 137:561–573. PMID: 14087676.
  10. Erritzoe D, Smith J, Fisher PM, et al. (2024). Antidepressants blunt the subjective effects of psilocybin but do not fully predict antidepressant response. Journal of Psychopharmacology. DOI: 10.1177/02698811241237870.
  11. Andrashko V, Novak T, Brunovsky M, et al. (2020). The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Frontiers in Psychiatry, 11:844. PMID: 33005153.
  12. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices. Journal of Psychoactive Drugs, 51(2):189–198. PMID: 30917760.
  13. Health Canada, case-by-case, physician-initiated access to psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
  14. FlΓΌckiger C, Del Re AC, Wampold BE, Horvath AO. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy, 55(4):316–340.
  15. Veraart JKE, Smith-Apeldoorn SY, Spijker J, et al. (2021). Ketamine treatment for depression: a review. Drugs, 81(14):1659–1680. PMID: 34170315.

Last updated: 2026-05-28. This article is reviewed every 6 months.

Find care near you

Explore ATMA CENA locations across Canada.